31 results on '"Hidalgo, D."'
Search Results
2. Influence of cavitation, pelleting, extrusion and torrefaction petreatments on anaerobic biodegradability of barley straw and vine shoots
3. Power-to-methane, coupling CO2 capture with fuel production: An overview
4. Selective separation of CH4 and CO2 using membrane contactors
5. A multi-waste management concept as a basis towards a circular economy model
6. The effect of feed composition on anaerobic co-digestion of animal-processing by-products
7. Long term testing of Microbial Fuel Cells: Comparison of different anode materials
8. The study of electrochemically active planktonic microbes in microbial fuel cells in relation to different carbon-based anode materials
9. Electrochemical and impedance characterization of Microbial Fuel Cells based on 2D and 3D anodic electrodes working with seawater microorganisms under continuous operation
10. 111 (PB101) - IK930, a novel TEAD inhibitor, sensitizes KRAS and EGFR mutant tumors to oncogene targeted therapy
11. 692TiP BRCA2men: An international, multicentre, observational and ambispective study to validate the predictive value of germline BRCA2 mutations for selecting the first-line of treatment in metastatic castration-resistant prostate cancer (mCRPC)
12. 644P BRCA2 status and intraductal [IDC] and cribriform [CRIB] histologic variants: Partners in prostate cancer (PC)?
13. 628P Treatment in CARD eligible metastatic castration resistant prostate cancer (mCRPC) patients according to the status of germline HRR mutations: Cabazitaxel (CBZ) vs enzalutamide/abiraterone
14. 612MO Clinical impact of somatic alterations in prostate cancer patients with and without previously known germline BRCA1/2 mutations: Results from PROREPAIR-A study
15. 864P - External validation of a prognostic score in first-line metastastic castration-resistant prostate cancer (mCRPC)
16. 889P - Circulating tumour cells (CTC) count and prostate-specific antigen (PSA) response measures in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with docetaxel (Doc)
17. 880P - Impact of treatment sequence in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Data from the prospective PROREPAIR-B study
18. 881P - Implications of single nucleotide polymorphisms (SNPs) in androgen related-genes in outcome of metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone (Abi) and enzalutamide (Enza)
19. 877P - Serum biomarkers of bone metabolism in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with radium-223 (Ra223): Results from a prospective multicentre study
20. 876P - Impact of germline mutations in homologous recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer (mCRPC)
21. LBA32 - PROREPAIR-B: A prospective cohort study of DNA repair defects in metastatic castration resistant prostate cancer (mCRPC)
22. 1674P - Exploratory study of CK-M30 and pHH3 expression in Circulating Tumor Cells (CTCs) as biomarkers of docetaxel (DOC) efficacy in metastatic castration resistant prostate cancer (mCRPC)
23. 1660P - ATM role in prostate cancer (PrCa) progression and survival
24. 844TiP - PROSENZA: Prospective multi-centre study of prognostic factors in castration resistant prostate cancer (CRPC) patients treated with enzalutamide (ENZ)
25. 834TiP - Randomized phase III trial of ipatasertib vs. placebo, plus abiraterone and prednisone/prednisolone, in men with asymptomatic or mildly symptomatic previously untreated metastatic castrate-resistant prostate cancer (mCRPC)
26. 843TiP - PRORADIUM: Prospective multicentre study of prognostic factors in castration resistant prostate cancer (CRPC) patients treated with radium-223
27. 825P - Limited value of currently used germline brca mutations predictive tools in prostate cancer
28. 826P - Prevalence and baseline clinico-pathological associations of germline deleterious mutations in DNA repair genes (gmDDR) in a metastatic castration resistant prostate cancer (mCRPC) prospective spanish cohort (PROREPAIR-B study)
29. 814P - Longer time from diagnosis to docetaxel treatment results in a shorter survival in metastatic hormonosensitive prostate cancer (mHSPC) patients treated with chemotherapy+androgen deprivation therapy (ADT)
30. 800P - Phase II study of prednisone-dexamethasone switch in metastatic castration resistant prostate cancer (mCRPC) patients treated with abiraterone and prednisone (AA+P)
31. Congenital lung malformation: 18 years of review
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.